Suppr超能文献

新型关注变异株 SARS-CoV-2 奥密克戎(B.1.1.529)的特征及其全球视角。

Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.

机构信息

Centre for Advanced Research (CFAR), Faculty of Medicine, King George's Medical University (KGMU), Lucknow, India.

The World Society for Virology (WSV), Al-Taif, Saudi Arabia.

出版信息

J Med Virol. 2022 Apr;94(4):1738-1744. doi: 10.1002/jmv.27524. Epub 2022 Jan 11.

Abstract

As the latest identified novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC), the influence of Omicron on our globe grows promptly. Compared with the last VOC (Delta variant), more mutations were identified, which may address the characteristics of Omicron. Considering these crucial mutations and their implications including an increase in transmissibility, COVID-19 severity, and reduction of efficacy of currently available diagnostics, vaccines, and therapeutics, Omicron has been classified as one of the VOC. Notably, 15 of these mutations reside in the receptor-binding domain of spike glycoprotein, which may alter transmissibility, infectivity, neutralizing antibody escape, and vaccine breakthrough cases of COVID-19. Therefore, our present study characterizes the mutational hotspots of the Omicron variant in comparison with the Delta variant of SARS-CoV-2. Furthermore, detailed information was analyzed to characterize the global perspective of Omicron, including transmission dynamic, effect on testing, and immunity, which shall promote the progress of the clinical application and basic research. Collectively, our data suggest that due to continuous variation in the spike glycoprotein sequences, the use of coronavirus-specific attachment inhibitors may not be the current choice of therapy for emerging SARS-CoV-2 VOCs. Hence, we need to proceed with a sense of urgency in this matter.

摘要

作为最新发现的新型严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)变异株,奥密克戎(Omicron)在全球的影响迅速扩大。与上一个变异株(Delta 变异株)相比,奥密克戎有更多的突变,这可能是其特征所在。考虑到这些关键突变及其影响,包括传染性增加、COVID-19 严重程度以及目前可用的诊断、疫苗和治疗方法效果降低,奥密克戎被归类为变异株之一。值得注意的是,这些突变中有 15 个位于刺突糖蛋白的受体结合域,这可能改变 COVID-19 的传染性、感染力、中和抗体逃逸和疫苗突破性病例。因此,我们目前的研究比较了 SARS-CoV-2 的奥密克戎变异株与 Delta 变异株的突变热点。此外,还分析了详细信息,以描述奥密克戎的全球视角,包括传播动态、对检测的影响和免疫,这将促进临床应用和基础研究的进展。总之,我们的数据表明,由于刺突糖蛋白序列的持续变异,使用冠状病毒特异性附着抑制剂可能不是治疗新兴 SARS-CoV-2 变异株的当前选择。因此,我们需要对此事保持紧迫感。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验